Investing.com -- Evercore ISI analysts highlighted several ... plans to launch test vehicles in 10 new cities in 2025, including San Diego and Las Vegas. Additionally, they note that Waymo will ...

Evercore ISI analyst Liisa Bayko upgraded Crispr Therapeutics (CRSP) to Outperform from In Line with a price target of $99, up from $60. Upcoming key catalysts could “usher in a new era,” says ...

NEW YORK, March 04, 2025--Evercore Wealth Management today announced the promotions of Paulo Coelho, Neza Gallitano and Alex Lyden to partner. Mr. Coelho and Ms. Gallitano are wealth & fiduciary ...

Centerview Partners, another New York boutique, opened a Paris office in 2020. And Evercore’s new initiative will face stiff competition from such storied French firms as Lazard and Rothschild ...

Evercore (NYSE: EVR) will host its 2nd annual Private Markets Forum in New York City on March 11-12, 2025. This year’s event will host executives and industry experts from over 20 leading ...

CenterPoint upgraded at Evercore ISI, seeing the stock returning to its pre-2024 10%-plus premium vs. 5% currently with visibility to a positive resolution of the Texas electric rate case.

CEO John Weinberg highlighted that 2024 was Evercore's second-best year for revenue ... 2024 and optimism for sustained growth, driven by new products and expanded client relationships.

Overall, the PPI report was consistent with Evercore's view that an "inflation scare" has "run a bit too far off a very limited set of new information since the start of the year," Guha said.

Evercore ISI raised the firm’s price target ... as Astera is set to benefit from momentum across multiple products and new product announcements likely coming over the next 12-to-18 months ...